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The purpose of this review is to analyse current options for fertility preservation in young 
women with breast cancer (BC). Considering an increasing number of BC survivors, owing to 
improvements in cancer treatment and delaying of childbearing, fertility preservation appears 
to be an important issue. Current fertility preservation options in BC survivors range from 
well-established standard techniques to experimental or investigational interventions. Among 
the standard options random-start ovarian stimulation protocol represents a new technique, 
which significantly decreases the total time of the in vitro fertilisation cycle. However, in 
patients with oestrogen-sensitive tumours, stimulation protocols using aromatase inhibitors 
are currently preferred over tamoxifen regimens. Cryopreservation of embryos and oocytes 
are nowadays deemed the most successful techniques for fertility preservation in BC patients. 
GnRH agonists during chemotherapy represent an experimental method for fertility 
preservation due to conflicting long-term outcome results regarding its safety and efficacy. 
Cryopreservation of ovarian tissue, in vitro maturation of immature oocytes and other 
strategies are considered experimental and should only be offered within the context of a 
clinical trial. An early pretreatment referral to reproductive endocrinologists and oncologists 
should be suggested to young BC women at risk of infertility, concerning the risks and 
benefits of fertility preservation options.       
 
 
 
 
 
Introduction 
Fertility preservation in breast cancer (BC) patients makes sense, since women who got 
pregnant following BC had a 41% reduced risk of death compared to women who did not get 
pregnant (PRR: 0.59), suggesting that pregnancies do not have an adverse effect on the 
outcome of BC. Therefore, BC survivors should not be denied the opportunity of future 
conception [1]. Although most physicians recommend that pregnancy should be delayed by 2 
to 3 years after BC, in early BC patients younger than 45 years of age, pregnancy that occurs 
at least 10 months after diagnosis does not jeopardize the prognosis and may actually confer 
significant survival benefit [2]. An increase in the incidence rate of BC in European women in 
their 20s and 30s has recently been reported, with the mean annual changes during the 1995-
2006 decade being 1.032 and 1.014, in women aged 20-29 and 30-39 years, respectively [3]. 
In the USA, the incidence of BC increased in 25- to 39-year-old women from 1.53 per 
100,000 in 1976 to 2.90 per 100,000 in 2009 [4]. However, the mortality rate in women under 
the age of 40 with BC has steadily been decreasing since the mid 80s, due to earlier diagnosis 
and recent advances in treatment [5].  
In the past decades more women have delayed childbearing until their 30s or later for 
different reasons. Unfortunately, there appears to be an increased BC risk with advancing 
maternal age at first childbirth: a 3,7 relative risk in women with an estimated first median age 
of 41 years, compared with those with an estimated first birth age of 23 years [6]. 
Consequently, a greater number of BC survivors are faced with reproductive concerns prior to 
completing their family. In a pilot survey of survivors’ attitudes, 76% of young childless 
women with cancer intended to have a child in the future and 35% of the survivors who 
already had at least one child wanted to have another [7].  
Therefore, international recommendations have been suggested regarding fertility 
preservation in these patients with cancer desiring pregnancy. The Update Panel of the 
American Society of Clinical Oncology (ASCO) recommends to health care providers, 
including oncologists, urologists, haematologists, surgeons and reproductive specialists to 
inform patients regarding potential threats to fertility, as early as possible, to allow the widest 
array of options for fertility preservation [8]. The European Society Medical Oncology 
(ESMO) Clinical Practice Guidelines recommended that young women desiring pregnancy 
following cancer diagnosis should be counselled on available fertility preserving options soon 
after diagnosis, to allow prompt referral to fertility specialists [9]. The First international 
consensus guidelines suggest that young women with BC, faced with specific physical, 
psychosocial and sexual issues, should address themselves to a multidisciplinary team of 
providers, including oncologists, breast nurses, social workers, psycho-oncologists, 
gynaecologists and fertility experts [10]. Although Anti-Mullerian hormone may be a useful 
marker of ovarian reserve before gonadotrophin administration in young BC patients at risk 
for poor-response or no response to ovarian stimulation, its clinical role in early BC and in 
predicting treatment-induced infertility needs to be defined [11].  
Currently available options to BC patients protecting their fertility range from well-
established standard techniques, such as ovarian stimulation for in vitro fertilisation (IVF) and 
embryo/oocyte cryopreservation, to investigational or experimental interventions as are, 
ovarian tissue cryopreservation, in vitro maturation (IVM) of immature oocytes and ovarian 
suppression with gonadotrophin releasing hormone (GnRH) agonists during chemotherapy 
[12]. Although many young women (68%) with BC do discuss fertility issues with their 
physicians before starting therapy and more than a half (51%) are concerned about becoming 
infertile after treatment, only a minority of women (10%) chooses to pursue available fertility 
preservation strategies [13]. Therefore, more efforts are necessary in order to achieve better 
patient understanding, to improve physicians
,
 ability to convey of fertility preservation 
possibilities to all women of reproductive age with cancer and to encourage participation in 
informed decisions about their therapeutic strategy and future reproductive ability [14].  
As the number of younger BC patients increases the aim of this review is to 
summarize the current knowledge on various fertility preservation options and consequently 
improve the communication between health care providers and patients about their benefits 
and disadvantages. 
 
Ovarian stimulation  
Ovarian stimulation for oocyte/embryo cryopreservation is currently the best established and 
the most preferred method for fertility preservation in BC patients. Although most young 
patients may conceive spontaneously, it is important to choose the appropriate ovulation 
induction protocol, because these patients have only one opportunity to undergo a single cycle 
of IVF before starting oncologic treatment. In most cases, ovarian stimulation protocols using 
gonadotrophins with GnRH antagonists and GnRH agonists for trigger should be preferred in 
fertility preservation cycles due to time restraints and the risk of ovarian hyperstimulation 
syndrome (OHSS) [15]. Instead of traditional ovarian stimulation with GnRH agonists, 
currently GnRH antagonists are routine practice in fertility preservation. Advances have been 
made from GnRH agonists to GnRH antagonists and to random start stimulation, in order to 
minimize the time from patient presentation to oocyte retrieval [16]. However, in cases of BC 
with oestrogen positive receptors several alternative and potentially safer protocols have been 
introduced using tamoxifen and aromatase inhibitors [17].  
Conventional-start ovarian stimulation with GnRH antagonists can be used in a fixed 
manner or in a flexible manner during the gonadotrophin stimulation. Although this approach 
still requires awaiting spontaneous menses, it decreases the interval to oocyte retrieval 
compared to traditional stimulation protocols. Alternatively, the administration of GnRH 
antagonists in the midluteal phase results in quicker initiation of gonadotrophins and GnRH 
antagonists, further reducing delays for BC treatment. Nevertheless, adhering to the 
conventional-start antagonist protocols could result in significant delay of cancer treatments 
[16,18]. 
Random-start ovarian stimulation protocol represents a new fertility preservation 
technique, when waiting for the next menstrual period to start the ovulation induction is not 
advisable, due to the urgency of the cancer treatment. It has been proposed to start in the late 
follicular phase or the luteal phase following spontaneous luteinizing hormone (LH) surge or 
after the ovulation induction with human chorionic gonadotrophin (hCG) or a GnRH agonist. 
Therefore, random-start ovarian stimulation provides a significant advantage by decreasing 
the total time of the IVF cycle, without compromising the oocyte yield and maturity before 
the cancer treatment. Since oocytes can be obtained before cancer treatment irrespective of 
the phase of the menstrual cycle, both random-start ovarian stimulation protocols are as 
effective as conventional-start regimens in the early follicular phase [17,19]. The average 
number of oocytes retrieved was similar between the groups (12.5 vs.15) [16]. 
Moreover, double ovarian stimulations during the follicular and luteal phases in the 
same menstrual cycle, provide more opportunities for retrieving more oocytes, in a short 
period of time in poor responders and newly diagnosed cancer patients needing fertility 
preservation. The primary outcome measured was the number of oocytes retrieved: stage one 
1.7 and stage two 3.5. Out of 167 oocytes collected 26 succeeded in producing one to six 
viable embryos cryopreserved for later transfer [20]. In assesing the clinical pregnancy rate in 
recipients of embryos from the same oocyte donor, obtained after ovarian stimulation initiated 
on day 2 or day 15 of the menstrual cycle, no differences were noted in pregnancy rates 
(62.5% vs. 58.3%) after both types of ovarian stimulation. Good pregnancy rates achieved on 
day 15 of the cycle may be useful information for patients with cancer undergoing fertility 
preservation [21].  
In the evaluation of the safety and efficacy of tamoxifen co-administration during 
conventional ovarian stimulation for fertility-preservation in BC patients, it was found that the 
high serum estradiol levels should be considered safe and that tamoxifen does not interfere 
with IVF results [22]. Aromatase inhibitors significantly reduce plasma oestrogen levels by 
competitively suppressing the activity of the aromatase enzyme. The third generation 
aromatase inhibitor, letrozole, is a drug of choice for the treatment of BC in women with 
oestrogen positive receptors and has recently been introduced as a new option for ovulation 
induction [23]. Furthermore, the use of aromatase inhibitors with gonadotrophins represents a 
safe and effective protocol for fertility preservation for women with BC [24]. Moreover, in 
patients requiring emergency fertility preservation, ovarian stimulation with the use of 
letrozole 2.5 mg/d, gonadotrophins, GnRH antagonists and hCG can be started at a random 
cycle date without compromising fertilization rates [25]. The use of GnRH agonist trigger 
instead of hCG, reduces oestrogen exposure and improves cycle outcomes, by increasing the 
yield of mature oocytes and embryos as well as decreasing the incidence of OHSS during 
ovarian stimulation with letrozole (5 mg/d) and gonadotrophins [26]. The largest prospective 
data with the longest follow up on the safety of ovarian stimulation with letrozole and 
gonadotrophins for fertility preservation suggests that it is unlikely to cause a substantially 
increased recurrence risk in BC patients, even in women who have not yet undergone breast 
surgery [27]. However, anastrozole, another third-generation aromatase inhibitor has a 
minimal suppressive effect on rising estradiol levels and its use is not recommended in 
fertility preservation cycles of oestrogen-sensitive cancer patients [28].  
 
Embryo and oocyte cryopreservation 
Embryo cryopreservation is the most established technique for fertility preservation for 
women with available partner or for women using donor semen, which  combines ovarian 
stimulation, oocyte retrieval and IVF. It usually takes 2–5 weeks and is therefore not 
applicable to patients who cannot delay BC treatment. According to Society for Assisted 
Reproductive Technologies, the current live-birth rate per transfer using frozen-thawed 
embryos in women under 35 years across the U.S. is 35.6%. [15,29,30]. The main methods of 
embryo cryopreservation are slow freezing and vitrification, with the latter gaining more 
popularity in recent years. Both vitrification methods (Irvine and Vitrolife) are more efficient 
(89.4% vs. 87.6%) than slow freezing (63.8%) for cryopreservation of human cleavage stage 
embryos in terms of post-warming survival rate [31]. Furthermore, vitrification of cleavage 
stage embryos yields a significantly better cycle outcome than slow freezing cryopreservation, 
according to the clinical pregnancy rate (20% vs.11.9%, respectively) [32]. The effectiveness 
of cryopreservation techniques is best evidenced by the success of cryopreserved embryos and 
the IVF outcome of frozen-thaw cycles, which have shown a satisfactory live birth rate (22%) 
in cancer patients for fertility preservation who have returned to use their embryos, over a 15-
year period of follow-up (1996–2011) [33]. 
 Freezing of mature oocytes for fertility preservation is an alternative to embryo 
cryopreservation and it is the preferred strategy regardless of the presence or absence of a 
partner [34]. The patient has to undergo ovarian stimulation and egg retrieval to obtain 
oocytes before chemotherapy, in order to avoid fertilizing a damaged egg and does not require 
IVF. Unlike embryo freezing, oocyte cryopreservation is an alternative option that can avoid 
ethical, religious and legal concerns [35]. Although human oocytes are extremely sensitive to 
temperature changes, cryoprotectants and ice formation, vitrification is more effective than 
slow cooling, as shown by higher survival rate and spindle assessment. Since embryos 
resulting from vitrified oocytes have significantly enhanced clinical pregnancy rates (38%), 
compared with embryos resulting from slow-rate freezing oocytes (13%), 
vitrification/warming is currently the most efficient method of oocyte cryopreservation 
[36,37]. These results were confirmed recently showing that vitrification success rates are 
superior to slow freezing, while the success rates of both techniques match those of fresh 
embryo transfer. However, the success rates with either technique tend to meaningfully 
decline after the age of 36 [38]. It should be noted that vitrification, a relatively recent clinical 
programme, has yielded over 1000 infants born worldwide and these figures are constantly 
increasing [39]. Consequently, in 2012, the American Society of Reproductive Medicine 
removed oocyte freezing from the experimental category for the patients who are unable to 
cryopreserve embryos and facing infertility due to gonadotoxic therapies, but not for the sole 
purpose of circumventing reproductive aging in healthy women [40]. 
Cryopreservation of immature oocytes represents an attractive alternative to 
cryopreservation of mature oocytes, because it does not require ovarian stimulation for BC 
patients with oestrogen sensitive tumours or who cannot delay chemotherapy. Following 
retrieval, immature oocytes can be cryopreserved either before or after IVM, which is mostly 
used in combination with other strategies rather than alone. Immature oocytes survive 
cryopreservation better than mature oocytes and after thawing these oocytes can be 
successfully matured in vitro and fertilized. Since the efficacy of cryopreservation of 
immature oocytes is very low, it still  remains an experimental option for fertility preservation 
[29,41-43]. However, IVM of immature oocytes prior to cryopreservation optimizes the 
reproductive potential because combined survival and maturation were significantly higher in 
fresh oocytes undergoing IVM (63.8%), compared with the postthaw IVM group (33.3%) 
[44].  Additionally, the combination of ovarian tissue cryopreservation with immature oocyte 
collection from the tissue followed by oocyte vitrification via IVM, represents another 
promising approach to fertility preservation in young women with cancer [45].   
 
Ovarian tissue cryopreservation 
According to a group of experts ovarian tissue preservation is the only fertility preservation 
possibility for prepubertal girls with cancer [34]. For BC patients who require urgent cancer 
treatment such as neo-adjuvant chemotherapy, ovarian tissue cryopreservation for future 
autotransplantation should be considered as the only fertility preservation option [46]. 
Ovarian tissue can be extracted by laparoscopy in order to harvest the ovarian cortex 
containing a lot of primordial follicles that are relatively resistant to freeze-thaw injury. It  
appears that the slow freezing technique makes the oocyte and granulosa cells more 
vulnerable whereas vitrification is a safer and more efficient method. Autotransplantation of 
the cortical strips after BC treatment is typically performed orthotopically by laparoscopy into 
the ovary or the pelvic peritoneum allowing natural conception [47]. The age limit for 
cryopreservation is a crucial factor because the chance of restoring the ovarian function is 
closely correlated to the number of follicles in the ovarian graft. Women should be up to the 
age of 35 to 37 because follicular density is still sufficient, otherwise the chance of pregnancy 
is low [48]. Worldwide, at least twenty two singletons and two sets of twins have so far been 
born with a total of 26 healthy children born as a result of orthotopic retransplantation of 
cryopreserved ovarian tissue [49]. In appears that the success rate may be higher in 
experienced transplantation centres because following transplantation into the peritoneum 
delivery rates were in 23% of cases and following overnight transportation of ovarian tissue 
delivery rates were up to 29% [50]. Unfortunately, the future of heterotopic grafting of 
cryopreserved ovarian tissue subcutaneously to the forearm or the suprapubic region and its 
clinical practicability for fertility preservation is still debatable [51].     
 
However, in women with Breast cancer antigen (BRCA) mutation–positive BC there 
are safety concerns considering fertility preservation. An early oophorectomy may be 
recommended to cryopreserve ovarian tissue of these patients before their risk for ovarian 
cancer increases with age. It appears that ovarian tissue reimplantation (rather than 
cryopreservation) is not considered to be a safe procedure in BRCA mutation carriers nor in 
advanced stage BC nor in invasive lobular BC. The use of preimplantation genetic diagnosis 
during IVF may be acceptable despite psychosocial and emotional difficulties [52]. Therefore, 
ovarian tissue transplantation remains an experimental fertility preservation approach due to 
insufficient data on the efficacy, safety and the reproductive outcomes – a possibility for 
patients carefully selected by centres with the necessary laboratory and surgical expertise 
[53]. 
 
Ovarian suppression with GnRH analogues 
Although adjuvant chemotherapy with tamoxifen have  conferred significant improvements in 
the overall survival of young BC patients, long-term adverse effects of cytotoxic treatment, 
such as premature ovarian failure (POF) and infertility have become increasingly important. A 
potential fertility preservation strategy may be administration of GnRH agonists before and 
during adjuvant chemotherapy. However, the results of a recent meta-analysis, suggest that 
concurrent use of GnRH agonists and chemotherapy in BC patients who did not use 
tamoxifen after chemotherapy, may not preserve ovarian function [54]. Therefore, ovarian 
suppression with GnRH agonists during chemotherapy has been considered experimental, 
although several recent studies offer both safety and efficacy for the use of GnRH agonists 
[55]. Adjuvant therapy with GnRH agonists alone or in combination with tamoxifen, produces 
results at least similar to those obtained with the different chemotherapy protocols in patients 
with hormone receptor-positive BC, with respect to overall survival. Therefore, it is advisable 
to choose GnRH agonist with tamoxifen for oestrogen receptor-positive BC patients, whereas 
for hormone receptor-negative women chemotherapy is possible to lead to reduction of the 
risk of recurrence. However, before asserting that adjuvant endocrine therapy produces 
similar results to adjuvant chemotherapy, it would be useful to assess the lymph node status, 
mitotic index and HER2 expression which may also influence the prognosis of BC  [56]. The 
annual report of the ASCO about the Clinical cancer advances in 2015, suggests good news 
for women with early-stage BC, desiring to have a child after BC treatment. Although POF is 
a common adverse effect in young women undergoing chemotherapy, new studies represent a 
promising way to preserve fertility, improve the long-term outcome results and the safety 
issue in BC patients. It appears that GnRH agonists temporarily shut down ovarian function, 
by introducing the patient in a postmenopausal state, protecting follicles and developing 
oocytes from chemotherapy damage in young women with BC [57]. In the first study, GnRH 
analogue administration with chemotherapy was associated with less POF and more 
pregnancies in premenopausal women with BC and hormone receptor–negative disease. 
Adding the hormone drug goserelin to standard chemotherapy cut the rate of POF from 22 to 
8%. After an extended follow-up period of 11,3 years the combination treatment approach 
resulted in successful pregnancies in 22 (88%) of the 25 women who attempted pregnancy, 
compared with 12 (67%) of 18 women who attempted pregnancy after receiving standard 
chemotherapy alone. The hormonal treatment did not increase the risk of miscarriage, 
pregnancy termination, or delivery complications and it even extended women's survival, 
compared with chemotherapy alone [58]. Another study reported similarly encouraging 
assesing results in mostly hormone receptor–positive BC, assessing the effect of triptorelin, 
on preventing POF in women with early-stage BC undergoing chemotherapy. After an 
average follow-up period of 7.3 years, there were eight pregnancies among the 148 women 
who received chemotherapy plus triptorelin with four pregnancies among the 133 women who 
received chemotherapy alone and triptorelin did not affect survival [59]. (Table 1) 
 
 
Table 1 Comparison of characteristics and outcomes of commonly used fertility 
 preservation options in BC patients    preservation options in BC patients  
 
 
Fertility 
preservation 
options 
/Characteristics 
 
Studies 
 
Advantages Disadvantages 
Live-birth 
rates 
Embryo 
cryopreservation  
Bedoschi G et al. [15]  
Kim SS et al. [29]  
Lawrenz B et al. [30] 
Barcroft J et al. [33] 
 
 
Most established and 
successful technique  
Pregnancy outcome  
similar or  higher than 
with fresh embryo transfer 
 
Ovarian stimulation, oocyte 
retrieval and IVF 
Required time 2–5 weeks 
Need a partner or donor 
Delay of treatment required 
Risk of OHSS 
22%-35,6%  
Mature oocytes 
cryopreservation  
Konc J et al.  [35] 
Smith GD et al.  [37] 
Cil AP et al. [38] 
Rodriguez-Wallberg KA et 
al. [39] 
 
Alternative to embryo 
freezing 
Partner not required 
No ethical, religious and 
legal concerns 
Over 1000 babies born 
wotldwide  
Not for the sole purpose in 
healthy women 
Ovarian stimulation, oocyte 
retrieval 
Cellular damage of oocytes 
Risk of OHSS 
Lower success rates after the 
age of 36 
13%-38% 
Cryopreservation 
and 
transplantation of 
ovarian tissue 
Mathias FJ et al. [47]  
von Wolff M  et al.   [48] 
Macklon KT et al. [49] 
Liebenthron JR et al. [50] 
Rodriguez-Wallberg KA et 
al. [52] 
Urgent BC treatment  
Prepubertal girls with 
cancer 
Partner not required 
Overnight tissue 
transportation to  
experienced 
transplantation centres  
26 healthy children born 
Laparoscopic removal with 
orthotopic retransplantation 
and heterotopic grafting of 
ovarian tissue 
Women should be up to the 
age of 35 to 37 
Risk of reintroduction 
cancerous cells 
Experimental option 
10%-29% 
Ovarian 
suppression with 
GnRH analogues 
during 
chemotherapy 
Vitek WS et al. [54] 
Franco JG et al. [56] 
Masters GA et al. [57] 
Moore HCF et al. [58] 
Lambertini M et al. [59] 
  
 
Reduction in the rate of 
POF from 22 to 8% 
Increase in pregnancy 
rates from 11 to 21%  
Non-invasive strategy 
No operation required 
No preservation of ovarian 
function 
Controversial results 
regarding efficacy and safety  
Experimental method  
 
18% 
Other experimental strategies 
Significant progress has been made in the development of other improved methods for 
fertility preservation such as in vitro follicle maturation, isolation of primordial follicles with 
transplantation in scaffolds, the potential role of AS 101, S1P and imatinib, which may 
revolutionise fertility preservation practice. However, further technological advances and 
research are required before these strategies can be utilised therapeutically in humans [60-64]. 
Ovarian tissue banking of thin cortical surface biopsies that contain predominantly primordial 
follicles is being increasingly offered to a variety of patients as a means of fertility 
preservation. The potential of this tissue could be realized by the development of in vitro 
systems, to support complete growth from the early primordial stages through to maturity. 
However, complete oocyte development in vitro from the primordial stage has been achieved 
only in mice [60]. Comparing macroporous alginate scaffolds with Matrigel for culturing 
frozen-thawed human primordial follicles in organ culture, it was shown that three 
dimensional alginate scaffolds are a promising putative in vitro technology for developing 
human primordial follicles [61]. Although cyclophosphamide activates the growth of the 
quiescent primordial follicles in mice and leads to loss of ovarian reserve, coadministration of 
an immunomodulator, AS101, reduces follicle activation, thereby increasing follicle reserve 
and rescuing fertility after cyclophosphamide and increasing the efficacy of 
cyclophosphamide against BC cell lines. Therefore, AS101 may be useful as an ovarian-
protective agent, which may be able to preserve fertility in female cancer patients [62]. 
Furthermore, Sphingosine-1-phosphate (S1P), a ceramide-induced death pathway inhibitor, 
can prevent cyclophosphamide or doxorubicin induced apoptotic follicle death in human 
ovarian xenografts. Therefore, S1P and its future analogues may be desirable for preserving 
fertility for patients undergoing chemotherapy [63]. Although two commonly used 
chemotherapeutic agents (cisplatin and doxorubicin) induce follicle loss in a markedly 
different pattern, imatinib mesylate provides selective protection only against cisplatin. 
Therefore, any treatment designed to protect the adverse effects on the ovary needs to be 
specific to the drug regimen to which the patient is exposed [64]. 
 
Conclusions 
Fertility is a major concern for young BC patients and information about fertility preservation 
options is of crucial importance. Random-start ovarian stimulation protocol represents a 
commendable technique, advisable in cases of urgent cancer treatment. In patients with 
oestrogen-sensitive tumours, stimulation protocols using letrozole are currently preferred over 
tamoxifen regimens. The most successful techniques for fertility preservation in BC patients 
are cryopreservation of embryos and oocytes. Ovarian suppression with GnRH agonists 
during chemotherapy represents an experimental method for fertility preservation due to 
conflicting results regarding its efficacy. Cryopreservation of ovarian tissue, IVM of 
immature oocytes and other strategies are considered investigational or experimental and 
should only be offered within the context of a clinical trial. The patients future chance of 
pregnancy should be discussed within an interdisciplinary medical team, made up of 
oncologists and fertility specialists, early in the early pretreatment consultation. 
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